Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels  by Berge, Kjetil et al.
N U T R I T I O N R E S E A R C H 3 4 ( 2 0 1 4 ) 1 2 6 – 1 3 3
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.n r j ou rna l . comKrill oil supplementation lowers serum triglycerides without
increasing low-density lipoprotein cholesterol in adults with
borderline high or high triglyceride levelsKjetil Bergea,⁎, Kathy Musa-Velosob, Melody Harwooda, Nils Hoema, Lena Burri a
a Aker BioMarine ASA, Fjordalléen 16, 0115 Oslo, Norway
b Intertek Cantox, Mississauga, Ontario, Canada L5N 2X7A R T I C L E I N F OAbbreviations: ANOVA, analysis of varianc
European Food Safety Authority; EPA, eicosap
cholesterol; NDA Panel, Panel on Dietetic Pr
omega-3 long-chain polyunsaturated fatty ac
⁎ Corresponding author. Aker BioMarine ASA,
E-mail address: kjetil.berge@akerbiomarin
0271-5317 © 2014 The Authors. Published by
http://dx.doi.org/10.1016/j.nutres.2013.12.00A B S T R A C TArticle history:
Received 14 August 2013
Revised 11 December 2013
Accepted 12 December 2013The aim of the study was to explore the effects of 12 weeks daily krill oil supplementation on
fasting serum triglyceride (TG) and lipoprotein particle levels in subjects whose habitual fish
intake is low and who have borderline high or high fasting serum TG levels (150–499 mg/dL).
We hypothesized that Krill oil lowers serum TG levels in subjects with borderline high or
high fasting TG levels. To test our hypothesis 300male and female subjects were included in
a double-blind, randomized, multi-center, placebo-controlled study with five treatment
groups: placebo (olive oil) or 0.5, 1, 2, or 4 g/day of krill oil. Serum lipids were measured after
an overnight fast at baseline, 6 and 12 weeks. Due to a high intra-individual variability in TG
levels, data from all subjects in the four krill oil groups were pooled to increase statistical
power, and a general time- and dose-independent one-way analysis of variance was
performed to assess efficacy. Relative to subjects in the placebo group, those administered
krill oil had a statistically significant calculated reduction in serum TG levels of 10.2%.
Moreover, LDL-C levels were not increased in the krill oil groups relative to the placebo
group. The outcome of the pooled analysis suggests that krill oil is effective in reducing a
cardiovascular risk factor. However, owing to the individual fluctuations of TG
concentrations measured, a study with more individual measurements per treatment
group is needed to increase the confidence of these findings.
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CVD in these patients [3]. One option to tackle high TG levels
and potentially decrease CVD risk is by dietary supplementa-
tion with the long-chain n-3 polyunsaturated fatty acids (n-3
LCPUFAs) that are known to decrease TG production and
increase TG clearance [4].
In the Canadian Natural Health Products Directorate
(NHPD) Fish Oil Monograph, the dose of n-3 LCPUFAs required
for TG reductions is 1 to 3 g/day. In Europe, the Panel on
Dietetic Products, Nutrition and Allergies (NDA Panel) of the
European Food Safety Authority (EFSA) recently concluded
that the n-3 LCPUFAs effectively reduce TG levels when con-
sumed at intakes of 2 to 4 g/day. There is some indication
from dose–response assessments that the n-3 LCPUFAs may
be efficacious in reducing fasting TG levels when consumed at
doses even lower than these recommended doses. In a recent
meta-analysis of randomized controlled trials, it was demon-
strated that TG levels are dose-dependently reduced by the n-
3 LCPUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) [5]. Even though there were only a limited number
of data points in the dose–response assessment at EPA and
DHA intakes of less than 1 g/day, there was some sugges-
tion that even modest intakes of the n-3 LCPUFAs could be
beneficial with regards to reducing fasting serum TG levels.
Likewise, in a dose- response assessment restricted to algal
sources of DHA, Ryan et al. demonstrated a dose–response
relationship between dose of DHA and the reduction in fasting
TG level [6]. Although this latter dose–response assessment
was restricted to studies conducted with algal DHA, it has
been reported that EPA and DHA have similar TG-reducing
effects when administered individually [7–9].
Krill oil is processed from Antarctic krill (Euphausia superba),
small shrimp-like animals of the crustacean superorder Eucar-
ida found in the Southern Ocean. Krill oil is a unique source of
EPA and DHA because unlike most other oils of marine origin,
the major part of EPA and DHA in krill oil occurs naturally in
phospholipid (PL) and not in TG form [10,11]. There are
indications that, compared to the delivery of EPA and DHA in
the TG form, the delivery of EPA and DHA in the PL form results
in higher tissue levels of EPA and DHA [12–15]. Krill oil is
characterized by a higher amount of EPA compared to DHA,
with a ratio of 2 to 1. While there is consensus in the scientific
literature that the dietary intake of both EPA and DHA (either
individually or in combination) can reduce elevated TG levels,
DHA (but not EPA) has been suggested to be responsible for a
simultaneous elevation in LDL-C seen particularly in patients
with very high (>500 mg/dL) TG levels [8,9,16].
In rodents, krill oil supplementation has been shown to
suppress lipid synthesis by up-regulating genes involved in
lipid oxidation and down-regulating those that are involved in
lipogenesis [17,18]. Blood TG and cholesterol levels were sig-
nificantly reduced after the administration of krill oil, both in
normolipidemic rats [19] and in rats with diet-induced hyper-
lipidemia [20]. Pre-clinical experiments also suggest that the
endocannabinoid system plays a major role in the action of
krill oil on fat distribution in obese rats [12,21].
Thus, the objective of the clinical study described herein
was to test our hypothesis that krill oil can lower serum TG
levels in humans with borderline-high or high fasting serum
TG levels (i.e., 150–499 mg/dL). Further, the study aimed toevaluate whether reductions in TG levels are achievable with
intakes of EPA and DHA from krill oil that are lower than those
currently recommended in the NHPD Fish Oil Monograph and
in the EFSA NDA Panel’s Scientific Opinion for TG lowering.2. Methods and materials
2.1. Study population and design
A randomized, double-blind, placebo-controlled, multi-center
study was performed by former Cetero Research at two United
States (U.S.) clinical research sites – one in Fargo, North Dakota
and the other in St. Charles, Missouri. To be included, subjects
had to be between 21 and 79 years of age, have a low habitual
fatty fish and seafood intake (defined as the intake of fatty
fish and seafoodat a frequencynot to exceed twicepermonth),
and have borderline high or high fasting serum TG levels
(defined as a fasting TG level of 150–499 mg/dL at Screening
visit, inclusive). Subjects were not eligible for study participa-
tion if they tested positive for drug or alcohol screens, tested
positive for pregnancy (for women of child-bearing potential),
were on lipid lowering medications or omega-3 supplementa-
tion, had a bodymass index (BMI) ≥35 kg/m2, had CVD or other
co-morbidities, bleeding disorders, hypertension, familial
hypercholesterolemia, coronary, peripheral or cerebral vascu-
lar disease, or allergy to fish or crustaceans. The primary ob-
jective of the study was to assess the effects on fasting serum
TG levels during 12 weeks of daily supplementation with four
different daily doses of SuperbaTM krill oil (0.5, 1.0, 2.0 and
4.0 g). Qualifying subjects were randomly and evenly allocated
into 5 study groups. Randomization was stratified by gender.
Subjects were instructed to avoid fish and seafood meals
36 hours before each clinic visit and to avoid consuming
alcohol in the 24 hours before each scheduled visit. A total of
5 visits were included: one for screening, one for randomiza-
tion and collection of baseline information, one at day 7 to
ensure the test products were being taken appropriately, and
two efficacy visits (6 and 12 weeks) when blood was drawn.
2.2. Study products
Krill oil capsules were provided by Aker BioMarine ASA (Oslo,
Norway) and olive oil (placebo) was obtained from Ruiz-
Canela e Hijos (Sevilla, Spain). The fatty acid and lipid profiles
of the study products are presented in Table 1. All subjects
were required to consume 8×500 mg capsules daily for the 12-
week intervention period; 4 capsules in the morning with
water before breakfast, and 4 capsules in the evening with
water before dinner. Subjects allocated to the placebo group
consumed 8 placebo capsules dailywhereas subjects allocated
to krill oil took 1, 2, 4 or 8 krill oil capsules and the remainder
as placebo. The group that was assigned 1 krill oil capsule per
day took it with the morning meal, otherwise the krill oil and
placebo capsules were distributed evenly amongst the morn-
ing and evening doses. The varying doses of krill oil (i.e., 0, 0.5,
1, 2, and 4 g/day) corresponded to daily intakes of EPA + DHA
of 0, 100, 200, 400, and 800 mg/day, respectively. All subjects
filled out compliance records daily, which included questions
on capsules count and time of intake.
Table 1 – Fatty acid and lipid composition of the products
administered
Fatty acids Placebo Krill oil
16:0 10.3 13.4
18:1 n-9 61.1 5.9
18:2 n-6 8.9 1.2
18:4 n-3 0 2.2
20:5 n-3 0 13.1
22:6 n-3 0 6.5
Totals and lipids 7.9 23.4
Saturated fatty acids 10.3 21.9
n-6 PUFA 8.9 1.8
n-3 PUFA 0.7 24.5
Total fatty acids 88.2 65.7
Triglycerides 86 30
Free fatty acids 0.2 3.8
Phospholipids 0 45
Total lipids 86.8 82.6
PUFA = polyunsaturated fatty acids.
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imperative to blind the subjects to the identity of the capsules.
Thus, tomask thedifferent colors of thekrill andplacebooils, the
gelatin capsules were black. To make the krill oil and placebo
capsules taste similar, a vanillin extract was added to all of the
capsules.Tomake thekrill andplacebooil capsulessmell similar,
theplacebocapsuleswere rubbedwithnegligible amountsofkrill
oil. All capsules were provided to subjects in 7×4 AM and PM
blister packs; each set of AM and PM blister packs provided a
subject with a week’s worth of dosing. The blister packs were
coded in a manner that maintained the blinding of the study.
Study subjects and personnel were blinded to the study.
2.3. Ethics
The study was conducted with approval of an Institutional
ReviewBoard and in accordancewithGoodClinical Practices and
the World Medical Association Declaration of Helsinki. All
subjects received appropriate oral and written information on
the background of the study and potential risks and benefits of
taking krill oil supplements. After comprehensive information
andtime forquestions,written informedconsentwasasked from
all subjects who wanted to enroll in the study. It was made clear
that at any time the subjects could withdraw their consent. The
study was registered at www.clinicaltrials.gov (NCT01415388).
2.4. Serum lipids, omega-3 index and safety assessments
Bodyweight and BMIweremeasured for all subjects during each
visit [screening, baseline, week 6 and week 12 (±3 days)]. Blood
from venipuncture for the assessment of serum lipids was
obtainedafter anovernight fast (≥ 12h) at screening andall visits.
After sitting for 30 min at room temperature, serum was
separated in silica gel tubes (BD Vacutainer) by centrifugation at
1,300 x g for 12min at room temperature. Serum analysis of total
cholesterol, LDL-C,HDL-C, andTGwasperformedusing standard
enzymaticmethodsonanOlympusAU5400orAU5431analyzer.
Blood for the assessment of the omega-3 index was collected
at baseline, 6 and 12 weeks after an overnight fast. It was
analyzed as described previously at Omegametrix GmbH (Mar-tinsried, Germany) [22,23]. In short, fatty acidmethyl esters from
red blood cells were analyzed by gas chromatography (GC2010,
Shimadzu, Duisburg, Germany) equipped with a SP2560 100-m
column (Supelco, Bellefonte, PA, USA), using hydrogen gas as a
carrier. Omega-3 indexwas given as EPA +DHA in red blood cells
expressed as a percentage of the total identified fatty acids.
Safetyassessments includedmeasurementsofbloodpressure,
pulse rate, body temperature, and the collectionof informationon
unsolicited adverse events at all visits, as well as 12-lead
echocardiogram (ECG), physical checkup, urinalysis, hematology
and clinical chemistry at the screening and end-of-study visits.
2.5. Statistical analyses
In order to detect a difference of 15% between each of the
dosing groups and the placebo group and assuming a two-
tailed alpha-level of 0.05, a standard deviation (SD) in percent
change from baseline in fasting serum triglycerides of 25%,
and 80% power, it was estimated that 60 subjects would be
required per group, and 300 subjects would be required, in
total. However, a large degree of intra-individual variationwas
observed in the TGmeasurements, which were not accounted
for in the power calculation. Thus, in addition to present the
TG level changes after 6 and 12weeks, themean changes from
baseline at 6 and 12 weeks in fasting TG in the four krill oil
groups were pooled in a time- and dose-independent manner
for comparison to the placebo group. By doing so, the
statistical power was increased and the relative (%) changes
from baseline in fasting TGs were compared using a Student’s
t-test. However, the pooling approach can only be seen as
explorative data analysis. The other lipid parameters (total
cholesterol, LDL-C and HDL-C) were not associated with large
intra-individual variability and were therefore compared to
the corresponding measures in the placebo group using an
analysis of variance (ANOVA), without pooling the data points
across the krill oil groups. The TG data presented in Table 4
was analyzed using ANOVA. The statistical analyses were
performed in JMP 10.0.2 (SAS Institute, Cary, NC). Changes
were considered statistically significant at p < 0.05. All data are
presented as means ± SD, unless otherwise specified.3. Results
3.1. Baseline subject characteristics
A total of 300 subjects were randomized into five groups and
were supplemented with either placebo (olive oil) or one of
four krill oil doses (0.5, 1, 2 or 4 g/day) (Fig. 1). Altogether, data
for 33 subjects were not included in the efficacy analysis. The
average of the Screening and Day 0 TG values was used as
baseline TG values. However, twenty-four subjects had a
fasting TG level within the range required for inclusion at
screening (i.e., between 150 and 499 mg/dL, inclusive); and not
at baseline, where the fasting TG levels were normal (i.e., <150
mg/dL). Data for these 24 subjects were excluded from the
analysis. Of the other 9 subjects whose data were not included
in the efficacy analysis, 1 subject was determined from the
dietary records to consume fatty fish more than twice per
month, 1 subject had adverse events (hypertension; not
Fig. 1 – Study design and disposition of participating study subjects. “TG < 150″ states the number of subjects that had
triglyceride levels below 150 at baseline and were excluded from final study analysis. “Excluded” includes subjects that
failed on inclusion/exclusion criteria, experienced adverse events or had major protocol deviations.
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study (two because of scheduling conflicts and one for
personal reasons) and 4 subjects had major protocol de-
viations (all four were not fasted at blood sampling).
Daily EPA and DHA doses are depicted in Table 2, as are
the numbers of subjects that could be used for the efficacy
assessments. More males (69%) than females participated in
the study. Most subject characteristics at baseline were not
significantly different between the groups. In particular mean
fasting serum TG values at baseline, which were approxi-
mately 232 mg/dL, were similar between the groups. Fasting
serum TG concentrations of <150 mg/dL (<1.7 mmol/L) are
considered to be normal, while values between 150–199mg/dL
(1.7-2.25mmol/L) define borderline hypertriglyceridemia, 200–
499mg/dL (2.25-5.65mmol/L) define high TGs, and >500mg/dLTable 2 – Baseline parameters and blood measurements of sub
Characteristics Overall Placebo 0.5 g krill oil
EPA dose (mg/day) 0 67
DHA dose (mg/day) 0 33
Number of subjects 267 52 53
Weight (kg) 89.6 ± 13.4 90.5 ± 14.1 90.1 ± 13.4
Height (cm) 1.74 ± 0.1 1.73 ± 0.11 1.73 ± 0.1
BMI (kg/m2) 29.6 ± 3 30.2 ± 3 29.9 ± 3.3
Age (y) 44.1 ± 12.3 43.5 ± 11 46.4 ± 12.7
Men (%) 69 65 66
White (%) 94 98 85
Omega-3 index (%) 3.68 ± 0.88 3.54 ± 1.05 3.66 ± 0.9
Triglycerides (mg/dL) 232.3 ± 71.5 236.5 ± 80.9 230.1 ± 71.4
Total cholesterol (mg/dL) 215.2 ± 35.7 207.9 ± 32.4 221.1 ± 37.1
HDL cholesterol (mg/dL) 43 ± 10.2 39.5 ± 9.3 44.5 ± 10.8*
LDL cholesterol (mg/dL) 127 ± 33.1 122.8 ± 4.7 132.7 ± 4.6(>5.65 mmol/L) define very high TGs. Also serum LDL-C con-
centrations were similar across the groups, with amean value
of 127 mg/dL.
Some significant differences between the treatment and
placebo groups at baseline were observed for HDL-C, BMI and
the omega-3 index (Table 2); nonetheless, overall, the subjects
had a low omega-3 index (between 3.5-4%) and BMI was
around 30 kg/m2.
3.2. Adverse events, body weight and blood pressure
Only three participants withdrew from the study (Fig. 1).
Overall, krill oil supplementation was well tolerated in all
groups and no serious adverse events related to study pro-
duct occurred during the study. There were two subjects withjects
1 g krill oil 2 g krill oil 4 g krill oil Pooled data for
krill oil groups
134 268 536 257.7
66 132 264 126.9
53 51 58 215
87.6 ± 14.7 91.7 ± 12.5 88.2 ± 12.1 89.3 ± 13.2
1.73 ± 0.09 1.75 ± 0.09 1.73 ± 0.09 1.74 ±0.1
29 ± 3.3* 29.7 ± 2.6 29.3 ± 2.9 29.5 ± 3
40.5 ± 13.1 44.3 ± 12.1 45.5 ± 11.9 44.2 ± 12.6
64 73 67 67
98 94 95 93
3.56 ± 0.81 4 ± 0.88* 3.65 ± 0.7 3.71 ± 0.84
238.9 ± 69.8 237.4 ± 73.1 220.2 ± 63 231.3 ± 69.2
209.4 ± 40.3 221.4 ± 36.1 216.2 ± 31.2 216 ± 36.3
42.1 ± 10.6 42.1 ± 9.2 46.2 ± 10* 43.8 ± 10.3
120.8 ± 4.6 133.1 ± 4.7 125.8 ± 4.4 128 ± 33.8
Table 3 – Omega-3 index levels of subjects in the placebo and krill oil supplementation after 6 and 12 weeks
Placebo 0.5 g krill oil 1 g krill oil 2 g krill oil 4 g krill oil
Baseline 3.54 ± 1.05 3.66 ± 0.9 3.56 ± 0.82 4 ± 0.88* 3.65 ± 0.7
6 weeks 3.44 ± 0.88 3.83 ± 0.75* 4 ± 0.75* 4.76 ± 0.86* 5.54 ± 0.87*
12 weeks 3.43 ± 0.77 3.97 ± 0.8* 4.19 ± 0.79* 5.17 ± 0.96* 6.3 ± 0.99*
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cellulitis. Other incidences of non-serious adverse events
that could possibly be related to study product intake were:
hypertension (1), soft stool (2), flatulence (1), upset stomach
(3), gastrointestinal discomfort (1), decreased appetite (1),
headache (1), taste change (1), diarrhea (4), fishy burps (1),
heartburn (1) and intermittent belching (1). Body weight and
blood pressure remained unchanged during the 12-week
study compared to baseline values in all five groups.
3.3. Omega-3 index
Compliance was confirmed by measuring the omega-3 index
(Table 3). The omega-3 index levels increased significantly in
all treatment groups after both 6 and 12 weeks of krill oil
supplementation, whereas the placebo group remained un-
changed. The omega-3 index changed by −3, 5, 12, 19 and 52%
from baseline in the placebo, 0.5, 1, 2 or 4 g krill oil groups,
respectively, after 6 weeks of supplementation. The corre-
sponding changes after 12 weeks were - 3, 8, 18, 29, and 73%.
3.4. Serum triglycerides
After 6 weeks, subjects in the 1, 2 and 4 g/day krill oil groups
revealed a 18.6 to 19.9 mg/dL decrease in fasting serum TG
levels, whereas the 0.5 g/day group showed a 13.1 mg/dL
decrease, when compared to baseline (Table 4). However, a
significant change inTGlevelswas lostat 12weeks inall groups.
Still, after 12 weeks of supplementation, subjects receiving krill
oil demonstrated a 10.2% decrease in fasting serum TG values,
when assessed by a pooled group- and time-independent
approach that included all the measurements after 6 and 12
weeks in the 0.5, 1, 2 and 4 g/day krill oil groups compared to
placebo (Fig. 2). The changes (%) from baseline in TG levels
amongst subjects supplemented with krill oil were significant
relative to the (%) change from baseline in TGs in the placebo
group (p = 0.0389). The change from baseline in fasting TGs was
3.9% in the placebo group and −6.3% in the krill oil group.
3.5. Serum lipoproteins
Total cholesterol (Fig. 3), LDL-C (Fig. 4), and HDL-C (Fig. 5) at 6
weeks and at 12 weeks remained unchanged relative to
baseline in the placebo and krill oil groups.Table 4 – Triglyceride levels (mg/dL) and change frombaseline o
and 12 weeks
Placebo 0.5 g krill oil
Baseline 236.5 ± 80.9 230.1 ± 71.4
Change after 6 weeks 12.0 ± 10.7 −13.1 ± 10.8
Change after 12 weeks 6.4 ± 12.7 −23.0 ± 12.74. Discussion
In order to accurately assess the efficacy of krill oil
supplementation in lowering fasting levels of TGs, the TG
levels have to be reliable. Studies wherein the primary
outcome variable is fasting TG level are challenging for several
reasons. Serum TG levels are known to show day-to-day
biological variations within individuals that can be as high as
25% in healthy fasted subjects when measured 2.5 months
apart [24]. Hypertriglyceridemic individuals can have even
greater fluctuations in fasting TG levels. Other reasons for
intra-individual variability in TG measures can be associated
with the preparation, processing, storage, and analysis of
blood samples. Despite attempts to minimize variability
during sample collection, storage, shipment, and measure-
ment, the individual biological fluctuations in fasting TGs
were large, thereby resulting in amuchhigher intra-individual
variation than accounted for in the power calculation
(Supplementary Fig. 1). Multiple TG measurements at the
individual visits, higher subject numbers or less dose groups
should be considered in future studies. In order to circumvent
these limitations, an explorative data analysis approach was
chosen to increase the statistical power of the study. Hence,
the mean of 6 and 12 weeks treatment TG measurements of
the four krill oil groups were pooled in a group- and time-
independent manner.
Across the 4 krill oil groups, themean intake of krill oil was
1.875 g/day, and the associated intake of EPA and DHA was
calculated to be 385mg/day. This theoretical intake of EPA and
DHA resulted in a 6.3% reduction from baseline in fasting TGs
and a 10.2% placebo-adjusted reduction from baseline in
fasting TGs. The efficacy of krill oil in reducing fasting serum
TG levels has been reported in other studies; however, the
doses of krill oil administered were larger than what was
administered in the current study. Ulven et al. demonstrated
that a daily dose of 2 g krill oil lowered fasting TGs in
participants with borderline high and high TG levels over a 7-
week period [25]. Krill oil has also been found to be effective in
hyperlipidemic patients without exclusion of lipid-lowering
medication by significantly reducing total cholesterol, LDL-C,
and TG, and by increasing HDL-C levels after 3 months of
supplementation; moreover, krill oil appeared more effective
than fish oil in reducing glucose, TG, and LDL-C levels [26]. Thef subjects in the placebo and krill oil supplementation after 6
1 g krill oil 2 g krill oil 4 g krill oil
238.9 ± 69.8 237.5 ± 73.1 220.2 ± 63
−19.9 ± 10.8* −19.9 ± 10.8* −18.6 ± 10.3*
−9.1 ± 12.8 −16.1 ± 12.7 2.1 ± 12.1
Fig. 2 – Placebo-adjusted changes (%) from baseline of fasted
triglyceride (TG), total cholesterol (Chol), high-density
lipoprotein cholesterol (HDL-C) and low-density lipoprotein
cholesterol (LDL-C) concentrations after 12 weeks of krill oil
supplementation. All four krill oil groupmeasurements were
pooled and the mean compared to the mean of the placebo
group. Significant changes are highlighted by (*), p < 0.05.
Fig. 4 – Comparison of mean serum values of LDL-C
(low-density lipoprotein cholesterol) in the placebo or 0.5,
1, 2 and 4 g krill oil treatment groups after 0, 6 and 12 weeks
of supplementation Bars represent means ± SD. No
significant changes (p < 0.05) were detected.
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placebo and, more importantly, information about the base-
line characteristics of the groups, particularly with respect to
medication use (i.e. lipid-lowering drugs). Very recently, a
pilot study demonstrated that daily supplementation of 4 g
krill powder (containing 60% krill oil) over 24 weeks showed a
significant TG-lowering effect in obese subjects [27]. The study
product, as well as the length of the study, is not directly
comparable with the current study, but the findings support
the hypothesis that krill oil has beneficial effects in subjects
with elevated levels of serum TGs.
The results of our study lend support to the suggestion
made by Musa-Veloso and colleagues that reductions in
fasting TG levels are possible with EPA and DHA intakes that
are less than the 2 g/day dose suggested by the EFSA NDA
panel. According to the equation of the first-order elimination
function presented by Musa-Veloso and colleagues, an intakeFig. 3 – Comparison of serum total cholesterol in the placebo
or 0.5, 1, 2 and 4 g krill oil treatment groups after 0, 6 and 12
weeks of supplementation. Bars represent means ± SD. No
significant changes (p < 0.05) were detected.of 385 mg/day of EPA and DHA is estimated to result in a
placebo-adjusted reduction from baseline in fasting TGs of
approximately 5.2% (Fig. 6). This estimated reduction un-
derestimates the theoretical pooled TG reduction in our study
of 10.2%. The reason for the higher-than-predicted reduction
in fasting TGs in our study is not clear. It may be that the first-
order elimination function used by Musa-Veloso et al. un-
derestimates reductions in TGs at lower intakes of EPA and
DHA; indeed, if the dose–response equation by Ryan et al. [6] is
used, which was linear as opposed to non-linear, but which
did not correct for changes in TGs observed in the placebo
group, the predicted reduction in fasting serum TGs at an EPA
and DHA intake of 385 mg/day is 12.4%. Although the dose–
response assessment undertaken by Ryan et al. included only
studies in which algal sources of DHA were administered, EPA
andDHA are generally similarly efficacious in reducing fasting
serum TGs, although DHA (but not EPA) tends to cause slight
increases in LDL-C [7,8]. Qualitatively, it appears from the data
points presented in Fig. 1 of the study by Ryan et al. [6] that theFig. 5 – Comparison of mean serum values of HDL-C
(high-density lipoprotein cholesterol) in placebo, 0.5, 1, 2
and 4 g krill oil treatment groups. Bars representmeans ± SD.
No significant changes (p < 0.05) were detected after 0, 6
and 12 weeks of supplementation.
Fig. 6 – TG reductions predicted by the first-order elimination
function modeled by Musa-Veloso et al. The placebo-
adjusted reduction in fasting TG with the consumption of
0.385 g/day of EPA and DHA from krill oil was 10.2%, a value
less than the 5.2% reduction predicted by the first-order
elimination function modeled by Musa-Veloso et al. [5].
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This observation is supported by the y-intercept of the equa-
tion of the line, which is −11.3%. Likely, the predicted reduc-
tion from baseline in fasting TGs is underestimated by the
model generated by Musa-Veloso et al. but overestimated by
the model generated by Ryan et al. [6].
Alternatively, the higher-than-expected reduction in fast-
ing TGs in our study may be due to the unique compositional
qualities of krill oil over other oils ofmarine origin, namely the
fact that krill oil is rich in PLs. This structural difference may
impact tissue uptake; indeed, it has been demonstrated that
PLs were a more efficient delivery form of n-3 LCPUFAs than
TGs [13,15,21]. The presence of PLs in krill oil [28] might be of
importance not only as a vehicle for transporting EPA and
DHA to tissues, but in lowering serum and liver cholesterol
and TG levels, whilst increasing HDL-C [29]. PLs might exert
these benefits by affecting biliary cholesterol excretion, intes-
tinal cholesterol absorption and gene expression for lipo-
protein metabolism. Some studies have demonstrated that
PLs containing n-3 PUFAs have more potent effects on liver
and blood plasma lipid levels, compared to PLs without n-3
PUFAs [30,31]. A speculative explanation for the observed in-
crease in serum TG levels after 12 weeks in comparison to 6
weeks of krill oil supplementation could be a beneficial effect
of krill oil on hepatic TG levels. Release of hepatic TG might
take more than 6 weeks to establish itself and could explain
the observed increase in serum TG levels after 12 weeks of
supplementation. This potential beneficial effect of krill oil on
the liver in addition to a high variation in TG measurements
could have caused the loss of significance in serum TG reduc-
tion at 12 weeks in particular in the 4 g krill oil group.
The reliability of plasma cholesterol measurements is
much lower than for TG measurements [24]. It was therefore
possible to compare individual treatment groups for changes
in cholesterollevels at weeks 6 and 12. In our study, no sig-
nificant effects of krill oil treatment on serumHDL-C and LDL-
C concentration could be observed at any time point. The EPA
to DHA ratio of 2:1 in krill oil might help to prevent an increasein LDL-C that has been observed with fish oil intake or the
intake of n-3 LCPUFA preparations containing predominantly
DHA [32,33].
Another suggested risk factor for CVD is the omega-3 index
that gives the percentage of EPA and DHA in total fatty acids in
red blood cells [34]. Red blood cell omega-3 fatty acids are highly
correlated with their corresponding atrial fatty acids [35].
In this study, the omega-3 index was significantly in-
creased at both time-points with all krill oil doses given and
confirmed regular study product intake. Furthermore, approx-
imately 2/3 of the omega-3 index increase during the study
period was already seen after the first 6 weeks.
Noteworthy, the omega-3 indexwent from 3.7 to 6.3% at 4 g
daily krill oil intake. Similar changes were associated with
decreased risk for sudden cardiac death in a prospective
cohort study by about 80% [36] and by a 90% reduction for risk
of primary cardiac arrest in a case–control study [37].
In conclusion, the hypothesis could be confirmed and the
combination of n-3 PUFA and PLs in krill oil has shown to be a
safe and promising intervention with regards to reducing
fasting serum TG levels and increasing omega-3 index, while
not increasing LDL-C or total cholesterol. Krill oil in combina-
tion with lifestyle changes that include diet and exercise may
therefore significantly reduce one’s risk for CVD morbidity
and mortality. However, due to the individual fluctuations of
TG concentrations measured, a potential biasing effect of TG
release from presumably fatty liver with time or other rea-
sons, a new study with more individual measurements per
treatment group and preferentially over a longer study period
would help to clarify the shortcomings of this study.
Supplementary data to this article can be found online at
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